Objective: Lysophosphatidylcholine (lysoPC) is abundant in atherosclerotic lesions and has potential immunomodulatory activities. This study is aimed to investigate effects of lysoPC on the interferon (IFN)-;-induced gene expression, focusing on T cell-directed CXC chemokines relevant to atherosclerosis. 
Introduction
The oxidative modification of LDL in the arterial wall has been suggested to play a key role in atherogenesis [1] . During the oxidation, phosphatidylcholine is converted to lysophosphatidylcholine (lysoPC) by phospholipase A 2 -like activity [2] , which is accumulated in atherosclerotic and inflammatory lesions [3] . Previous reports have shown that lysoPC has potential immunomodulatory functions. LysoPC induces the expression of multiple genes relevant to atherosclerosis and inflammation in endothelial cells [4] [5] [6] [7] [8] , macrophages [9] , T cells [10] , and vascular smooth muscle cells. Products of lysoPC-induced genes in endothelial cells include endothelial-leukocyte adhesion molecules, such as vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 [6, 7] , which support the accumulation of mononuclear leukocytes in the lesion. LysoPC also functions as a chemoattractant for T cells and macrophages [11, 12] . Moreover, lysoPC increases IFN; production and CD40 ligand expression on activated T cells [10, 13] . Inasmuch as CD40 ligand-CD40 interactions are required for T cell-mediated B cell differentiation and the generation of the IFN;-producing Th1 subset of CD4+cells, these effects of lysoPC suggest the involvement of lysoPC in the selection of the Th1/Th2 response. Interestingly, lysoPC is also implicated in the pathogenesis of the autoimmune disease systemic lupus erythematosus [14] [15] [16] .
IFN; is a proinflammatory cytokine secreted by Th1 cells and promotes immune and inflammatory responses through the activation of various types of cells, including macrophages, smooth muscle cells, and endothelial cells. IFN; potentiates VCAM-1 expression induced by proinflammatory cytokines, such as tumor necrosis factor A (TNFA) in endothelial cells [17] . IFN; also induces the expression on endothelial cells of CD40, which interacts with the CD40 ligand expressed on CD4+T cells to induce the production of adhesion molecules, E-selectin, VCAM-1, and ICAM-1 on endothelial cells [18] . These effects of IFN; suggest its involvement in the accumulation of immune cells through the activation of endothelial cells in inflammatory lesions, including atherosclerotic lesions. Furthermore, IFN; induces the expression of activated T cell-directed chemokines IP-10, Mig, and I-Tac in endothelial cells, macrophages, and smooth muscle cells [19] . These chemokines interact with CXCR3 of activated T cells, predominantly Th1, which secretes IFN; [20, 21] . Recent in vivo studies have provided evidence that IFN; secreted by Th1 has proatherogenic properties [22, 23] , and that IP-10, Mig, and I-Tac are expressed in endothelial cells, macrophages, and smooth muscle cells in atherosclerotic lesions [19] . Therefore, IFN; secreted by Th1 could promote the recruitment of Th1 through induction of IP-10, Mig, and ITac expression in a paracrine manner and potentiate atherogenesis.
Upon binding to its receptor, IFN; activates Janus kinase (JAK)-signal transducer and activator of transcription (STAT)-1 pathway [24, 25] . Homodimer of phosphorylated STAT-1A and complexes containing phosphorylated STAT-1A and p48 act as activated forms of transcription factors. Recently, it has been reported that STAT-1A and p48 are essential for IP-10 [25] and I-Tac [26] gene induction by IFN; and are induced by IFN;. IRF-1 is another transcription factor, which is induced and activated by IFN;, and required for the induction of VCAM-1 [17] , guanylate binding protein (GBP)-1 [27] , and inducible nitric oxide synthetase.
In the light of the potential immunomodulatory role of lysoPC and the importance of IFN; in immune response and atherogenesis, we investigated the effects of lysoPC on the endothelial expression of IFN;-induced genes, especially the Th 1-directed chemokines IP-10, I-Tac, and Mig, and the IFN;-activated transcription factors STAT1A, p48, and IRF-1.
Materials and Methods

Materials
L-A-lysoPC (from egg phosphatidylcholine) was purchased from Avanti Polar Lipids. Recombinant human IFN; and TNFA were obtained from R&D Systems (Minneapolis, MN, USA). M199 medium, penicillin G, L-glutamine, and fetal calf serum (FCS) were from Invitrogen (Carlsbad, CA, USA).
Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cords using collagenase (Collaborative Research, Lakewood, NJ, USA) and cultured in M199 medium supplemented with endothelial cell growth supplement (Sigma, St. Louis, MO, USA), heparin (from porcine intestinal mucosa, Sigma), antibiotics (100 U/ml penicillin G and 100 mg/ml streptomycin), l-glutamine, and 20% FCS. Confluent cells of three to five passages were used for this study. For stimulating HUVECs, M199 medium containing 5% FCS, l-glutamine and antibiotics was used for all experiments. This study conformed to the declaration of Helsinki, and informed consent was obtained from all donors of umbilical cord.
Northern blot analysis
Northern blot analysis was performed, as previously described [28] . To prepare cDNA probes for IP-10, Mig, ITac, GBP-1, STAT-1A, and p48, RT-PCR was carried out using total RNA extracted from HUVECs treated with IFN; and TNFA. The PCR products were subcloned into pGEM-T or pGEM-T easy vector (Promega) and sequenced using an ABI PRISM 310 Genetic Analyzer. The following primers were used for PCR: IP-10; 5V-CTCTAAGTGGCATT-CAAGGA and 5V-AACCCCAAAGCAGAAAGATT, Mig; 5V-AAGGAACCCCAGTAGTGAGA and 5V-TTGTGAGT-GGGATGTGGTTG, I-Tac; 5V-TTCCCCATGTTCAAAA-GAGG and 5V-TAAAACAAACCAAATGATGC, GBP-1; 5V-GGAACCGAGGAAGGGGATAC and 5V-CTACT-GCTGGTCATCTGGAA, STAT-1A; 5V-AGTGGAGTG-GAAGCGGAGAC and 5V-ATCACCACAACGGG-CAGAGA, p48; 5V-AAGTGGAGAGTGGGCAGTTT and 5V-AGAACTGTGCTGTCGCTTTG. The following cDNA fragments were also used: a 1.7-kb Sac I fragment of IRF-1 cDNA kindly provided by Dr. Tucker Collins (Brigham and Women's Hospital, Boston, MA) and a 0.9-kb HindIII/ AccI fragment of GAPDH cDNA purchased from ATCC.
Western blot analysis
Following experimental treatment of HUVEC, wholecell lysates were prepared using RIPA lysis buffer (1X phosphate buffer saline, pH 7.4, 1% Nonidet pÀ40, 0.5% sodium deoxycholate, 0.1% SDS, 10 Ag/ml PMSF, 1 Ag/ml aprotinin). Twenty micrograms protein of whole-cell lysate was separated by SDS-polyacrilamide gels electrophoresis under reducing conditions, transferred to nitrocellulose in 25 mM Tris, 192 mM glycine-5% methanol at 150 V for 1 h. Antibodies specific for STAT-1a, p48, and IRF-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at 1:200 dilution. Immunoreactive proteins were detected according to the enhanced chemiluminescent protocol (Amersham) using 1:1500 horseradish peroxidase-conjugated goat antirabbit secondary antibody.
ELISA
Culture supernatants were collected, and concentrations of human IP-10 and Mig were measured by sandwich ELISA using a protein detector ELISA kit (KPL, Gaithersburg, MD, USA) according to the manufacturer's instructions. Anti-IP-10 or Mig monoclonal antibody (R&D Systems) as a capture antibody and rabbit anti-IP-10 or Mig polyclonal antibody (PeproTech, London, UK) as a detection antibody were used. Optical densities were measured with a plate reader (EAR400, SLT-Lab instruments). IP-10 and Mig concentrations were calculated after preparing standard curves using recombinant human IP-10 or Mig (R&D Systems).
Nuclear run-off assay
Nuclear run-off experiments were performed, as previously reported [29] with some modifications. In brief, confluent HUVECs were stimulated with appropriate stimulants and scraped into PBS. The cell pellets were resuspended in NP-40 lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl, 0.5% NP-40, 0.25 TIU aprotinin (Sigma), and 0.1 mM PMSF). Then, the nuclei were resuspended in glycerol storage buffer (10 mM TrisHCl pH 8.3, 0.1 mM EDTA, 1 mM DTT, and 40% glycerol) at 6Â10 6 nuclei per 100 Al, snap frozen in liquid nitrogen. The transcription reaction was carried out by mixing nuclei with an equal volume of 2Â reaction buffer (10 mM Tris-HCl pH 8.0, 5 mM MgCl 2 , 300 mM KCl, 0.1 mM PMSF, 0.5 mM DTT, 1 mM each of unlabelled ATP, CTP, and UTP, 250 U/ml RNase inhibitor (Promega, Madison, WI, USA) and 30 mCi [a-32P] UTP) and incubated at 30 8C for 30 min. Transcribed labelled RNA was isolated using Isogen-LS (Nippongene, Tokyo, Japan). Denatured plasmids containing cDNA fragments of IP-10, Mig, I-Tac, and GAPDH were immobilized onto nylon membrane (Hybond LX; Amersham, Piscataway, NJ, USA) and hybridized with an equal amount of newly transcribed RNA for 36 h. The membrane was autoradiographed with a Fujix Bioimage Analyzer BAS200 (Fuji Photo Film, Japan).
Preparation of IP-10 promoter/ luciferase construct
A 971-bp IP-10 promoter fragment was generated from genomic DNA with IP-10 U (5V-GAACCCCATCGTAAAT-CAACCTG-3V) and IP-10 L (5V-GCAGCAAATCA-GAATGGCAGTTTG-3V) as the forward and reverse primer, respectively, using KOD101 DNA polymerase (TOYOBO, Osaka, Japan). This DNA fragment was cloned into the pGEM-T easy vector (Promega) and amplified. Then using the vector as a template, PCR was conducted with IP-10 U-Bgl II and IP-10 L-BglII as primers to introduce a BglII site. The PCR product was digested to a 355-bp distal and a 616-bp proximal fragment with BglII.
The 616-bp fragment has the 5V-flanking region of the human IP-10 gene from À519 to +97 and contains an IFNstimulated response element and two NFnB sites which were required for IP-10 gene expression induced by IFNg or a combination of IFNg and TNFa. The 616-bp fragment was gel purified and cloned into the promoterless pGL3-basic vector (Promega) to give the plasmid Bgl IP-10. The orientation and vector insert boundaries were verified through digestion with a restriction enzyme and sequence analysis.
Transient transfection assay
HUVECs were transiently cotransfected with the IP-10 promoter/firefly luciferase construct (Bgl-IP-10) and pRL-TK plasmid as an internal control, containing the herpes simplex virus thymidine kinase promoter upstream of the Rennila luciferase gene (Promega). HUVECs on 12-well plates were transfected with 0.8 Ag of DNA per well for 4 h, using Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's protocol. Forty-eight hours after transfection, cells were stimulated with IFNg and/or lysoPC for 6 h. Then the cells were harvested, and a dual luciferase assay (Promega) was performed.
Statistical analysis
Differences were analyzed by one-way ANOVA and then by Fisher's test. A p value of b0.05 was regarded as significant.
Results
LysoPC selectively inhibits IFNc-induced IP-10, I-Tac, and Mig mRNA expression in HUVECs
IFNg induced expression of IP-10, I-Tac, and Mig mRNA in HUVECs in a time-dependent manner (Fig.  1A) . Increased levels of IP-10, I-Tac, and Mig mRNA were detectable at 4-h stimulation, reached a peak after 8 h, and were maintained for at least 24 h. We also examined mRNA expression of IRF-1, one of IFNginduced and activated transcription factors, and GBP-1, an IRF-1-dependent gene. IFNg-induced IRF-1 and GBP-1 mRNA expression reached maximal levels after 4 h and was sustained for at least 24 h. LysoPC transiently inhibited IP-10, I-Tac, and Mig mRNA expression induced by IFNg. These inhibitory effects of lysoPC were observed at 4 h and 8 h and almost abolished at 24 h (Fig. 1A) . Dose-response experiments revealed that these inhibitory effects were also dose-dependent; the effects were observed at 40 AM, and mRNA signals became almost undetectable at 80 AM of lysoPC with 8 h of stimulation (Fig. 1B) . In contrast, IFNg-induced IRF1 and GBP-1 mRNA expression was not affected by lysoPC even at 80 AM for up to 24 h (Fig. 1A ). Furthermore, we tested whether lysoPC inhibits the gene expression of other IFNg-inducible transcription factors, STAT-1a, and p48. As shown in Fig. 1C , lysoPC dose dependently inhibited the IFNg-induced mRNA expression of STAT-1a but not p48 and IRF-1.
Additionally, lysoPC inhibited the mRNA expression of IP-10, I-Tac, and Mig induced by TNFa and IFNg (Fig. 1D) , whose combination can synergistically induce the expression of these chemokines (data not shown). Furthermore, we observed that other phospholipids, phosphatidylcholine, and lysophosphatidic acid did not affect IP-10, Mig, and I-Tac mRNA expression induced by IFNg (Fig. 1E) .
Because the protein synthesis inhibitor cycloheximide inhibited IFNg-induced IP-10, Mig, and I-Tac mRNA expression ( Fig. 2A) , we next studied whether an inhibition of new protein synthesis of STAT1-a, other transcription factor(s) we did not examine in the present study, or factor(s) that influence posttranscriptional regulation could be involved in the inhibitory effect of lysoPC. HUVECs were first pretreated with IFNg for 24 h to produce enough IFNginducible protein and then treated with IFNg alone or IFNg and lysoPC for 6 h. LysoPC appeared to reduce the IFNginduced expression of IP10, Mig, and I-Tac mRNA (Fig. 2B ), although pretreatment with IFNg for 24 h induced STAT-1a and p48 protein expression (Fig. 2C) . This result suggests that lysoPC does not inhibit the expression of CXC chemokines induced by IFNg via inhibition of STATa and p48.
LysoPC inhibits IFNg-induced IP-10 and Mig protein expression in HUVECs
To investigate the effect of lysoPC on IP-10 and Mig protein expression induced by IFNg, the secretion of chemokines into the culture medium of HUVECs was analyzed by ELISA (Fig. 3) . The amount of Mig secreted from HUVECs was about twofold greater than that of IP-10 ( Fig. 3) . LysoPC inhibited IFNg-induced IP-10 and Mig secretion in a dose-dependent manner. The inhibitory effect was observed from 40 AM and almost abolished at 80 AM of lysoPC.
LysoPC does not inhibit IP-10, Mig, and I-Tac gene expression induced by IFNc or a combination of IFNc and TNFa at the transcriptional level
To investigate whether lysoPC transcriptionally inhibits these mRNAs, we first performed nuclear run-off assays. The results showed that IFNg increased the rate of transcription of the Mig, I-Tac, and IP-10 genes but only slightly (Fig. 4A, C) . However, a combination of IFNg and TNFa markedly increased the transcription rate of these genes (Fig. 4B, D) . The increase in transcription of the IP-10, I-Tac, and Mig genes was 1.3-fold, 1.1-fold, and 1.5-fold by IFNg, and 9.4-fold, 6.4-fold, and 5.9-fold by IFNg and TNFa, respectively, compared with medium alone (Fig  4C, D) . Unexpectedly, lysoPC did not inhibit but potentiated IP-10, I-Tac, and Mig transcription induced by IFNg alone or in combination with TNFa (Fig. 4) .
To confirm the above results, HUVECs were cotransfected with Bgl-IP-10 and pRL-TK plasmids, and luciferase activities were analyzed. As shown in Fig. 5 , IFNg slightly but reproducibly activated the IP-10 promoter. As previously reported, TNFa effectively and TNFa and IFNg synergistically increased IP-10 promoter activity. As expected from the results of the nuclear run-off experiments, lysoPC enhanced IP-10 promoter activity in the presence of IFNg or a combination of IFNg and TNFa. Thus, our results indicate that lysoPC inhibits IP-10, Mig, and I-Tac not at the transcriptional level but at the posttranscriptional level.
LysoPC decreases the stability of Mig, I-Tac, and IP-10 mRNA in endothelial cells
We investigated the effect of lysoPC on the stability of IP-10, Mig, and I-Tac mRNA accumulated in response to IFNg. The decay of the mRNA was chased for 18 h because a combination of IFNg and actinomycin D seems toxic to HUVECs at 24 h. As shown in Fig. 5 , the half-life of IP-10 mRNA was approximately 12 h, while that of Mig as well as I-Tac was more than 18 h in endothelial cells. Interestingly, lysoPC enhanced the decay of IP-10, Mig, and I-Tac mRNA (Fig. 6) , indicating a decrease in the stability of the mRNA of these chemokines.
Discussion
In the present study, we demonstrated that lysoPC inhibited IP-10, I-Tac, and Mig mRNA expression induced by IFNg. In addition, lysoPC inhibited the IFNg-induced expression of STAT-1a mRNA but not IRF-1, GBP-1, and p48 mRNA. The results suggest that lysoPC selectively inhibits some of the IFNg-inducible genes in HUVECs. STAT-1 is a well-known transcription factor playing a pivotal role in IFNg signalling. Recently, it has been revealed that IFNg activates both STAT-1-dependent and STAT-1-independent pathways [24] . IRF-1 is a transcription factor, which is induced by IFNg, and is reported to be involved in the induction of GBP-1 gene expression [27, 28] . Because lysoPC did not inhibit IRF-1 and GBP-1 mRNA expression induced by IFNg, lysoPC appears to inhibit IRF-1-independent pathway(s) in HUVECs. We also demonstrated in the present study that lysoPC inhibited the mRNA expression of CXC chemokines induced by IFNg, even STAT1a mRNA expression which was highly induced by IFNg pretreatment. This result and the result that lysoPC did not inhibit STAT-1-dependent IRF-1 expression suggest that STAT1a is not involved in the inhibitory effect of lysoPC.
Previous reports have shown that IFNg regulates IP-10 and Mig mRNA expression at the transcriptional level in macrophage and fibroblast cell lines [25, 30] . However, our data demonstrated that the transcriptional up-regulation of these chemokines by IFNg alone was marginal in endothelial cells, although at the mRNA and protein level, it was induced effectively. Conversely, TNFa activated the IP-10 promoter effectively but did not induce IP-10 expression at the mRNA or protein level in HUVECs. These results suggest that IFNg-induced IP-10 mRNA expression could involve posttranscriptional regulation. Indeed, some recent reports have shown that IFNg can up-regulate gene expression by influencing posttranscriptional regulation, such as pre-mRNA splicing, mRNA stability, or unknown mechanisms [31, 32] . The present study demonstrated that lysoPC enhanced the degradation of IP-10, Mig, and I-Tac mRNA induced by IFNg. Taken together, it is likely that lysoPC destabilizes the mRNA of these chemokines accumulated by IFNg via posttranscriptional mechanism(s).
Th1 cytokines, such as IFNg and IL-2, are abundant in atherosclerotic lesions, especially early lesions, whereas very small amounts of Th2 cytokines, such as IL-4 and IL-10, are detected in advanced human lesions [33] . Recent reports have shown that Th1 cytokines are proatherogenic, and Th2 cytokines are potentially antiatherogenic. Zhou et al. [34] have demonstrated that apoE-deficient mice showed a Th1/Th2 switch at a very advanced stage in severe hypercholesterolemic conditions. Although there is no direct evidence, lysoPC-induced down-regulation of these Th1-directed CXC chemokines might contribute to the shifting of T cell responses from Th1 to Th2 in focal areas of atherosclerotic lesions. In addition, IP-10, I-Tac, and Mig are natural antagonists for CCR3 [35] , a receptor for Th2-specific chemokines, including eotaxin, which is expressed in atherosclerotic lesions. Therefore, inhibition of CCR3 antagonists by lysoPC may promote Th2 cell accumulation in atherosclerotic lesions.
IP-10, I-Tac, and Mig also function as angiostatic factors [36] . Because plaque neovascularization is suggested to be an important factor promoting atherosclerotic progression and plaque rupture [37, 38] , inhibition of angiostatic CXC chemokines by lysoPC may promote the rupture of atherosclerotic plaques. In addition, IP-10 can induce the migration and proliferation of smooth muscle cells [39] . Therefore, the inhibition of IP-10 production by lysoPC might result in a reduction of smooth muscle cell migration and the secretion of collagen in the formation of the fibrous cap, which could lead to plaque rupture.
To our knowledge, there are few in vivo studies showing that lysoPC is involved in the development of atherosclerosis. Interestingly, lysoPC is implicated in the pathogenesis of autoimmune diseases, such as SLE [14] [15] [16] , and patients with SLE exhibit a higher incidence of cardiovascular diseases [40] . In addition, recent studies suggested that autoimmunity could result from defects in the ability to scavenge apoptotic bodies [14, 15] ]. In this regard, lysoPC is speculated to be a component of the phagocyte attraction signals that are secreted by cells undergoing apoptosis [14] . Aprahamian et al. [15] have studied the link between autoimmune disease and atherosclerosis and demonstrated that lysoPC delays the clearance of apoptotic cells, allowing cells to enter the late stages of apoptosis, and thereby promotes vascular inflammation and then the progression of atherosclerosis. Furthermore, mice lacking G2A, a receptor of lysoPC, develop lupus-like autoimmune disease [16] . So far, G-protein coupled receptors G2A and GPR4 have been identified as receptors of lysoPC [41, 42] . G2A is expressed on T cells and macrophages, while GPR4 mRNA is expressed in endothelial cells (our unpublished data). To obtain evidence in vivo that lysoPC really plays a roll in the development of atherosclerosis, studies using apoEÀ/Àmice crossed with G2A-or GPR4-deficient mice should be conducted.
In summary, the present report demonstrates, for the first time, that lysoPC selectively inhibits IFNg-induced expression of IP-10, I-Tac, and Mig in cultured endothelial cells. Mechanisms responsible for the inhibitory effects of lysoPC involve, at least in part, a decrease in mRNA stability. The inhibition of IP-10, Mig, and I-Tac expression by lysoPC might be functionally implicated in the regulation of T cellmediated immune responses, intima neovascularization, and fibrous cap formation during the development of atherosclerosis.
